Issue: FDA and Drug Regulation
     
 
En Español

The Power of Independent Thinking

←  ISSUES
Issues
›
Regulation
›
FDA and Drug Regulation
›
Commentary

Showing 111 - 120 of 196 Results.

The Economy Is Not a Series of Supply Chains
Donald J. Boudreaux | Commentary | Apr. 13, 2020
COVID-19 Counter Measures Should Be Age Specific
Martin Kulldorff | Commentary | Apr. 11, 2020
These Changes Could Mobilize Key Medical Personnel to Fight a Pandemic
C. Ronald Kimberling | Commentary | Apr. 10, 2020
Why Central Planning by Medical Experts Will Lead to Disaster
Gary M. Galles | Commentary | Apr. 9, 2020
Do the Media Hate Trump More Than They Hate the Virus?
John C. Goodman | Commentary | Apr. 6, 2020
Drug Is Safe and Sometimes Works, Let All COVID-19 Patients Take It
Ronald L. Trowbridge | Commentary | Apr. 2, 2020
How Would Free Market Health Care Respond to the Coronavirus?
John C. Goodman | Commentary | Mar. 28, 2020
Trust Private Enterprise to Flatten the Curve
Raymond J. March | Commentary | Mar. 27, 2020
Political Promises Won’t Lower Insulin Prices
Raymond J. March | Commentary | Mar. 12, 2020
House Bill Seeking Price Controls on Drugs Would Cause Millions to Die
Ronald L. Trowbridge | Commentary | Dec. 21, 2019






  • Catalyst
  • Beyond Homeless
  • MyGovCost.org
  • FDAReview.org
  • OnPower.org
  • elindependent.org
© 2024 INDEPENDENT INSTITUTE, 100 SWAN WAY, OAKLAND CA 94621‑1428 | (510) 632‑1366 | (510) 568‑6040 FAX | SEND EMAIL